Long-term Effectiveness of COVID-19 Vaccines Against Symptomatic and Asymptomatic Infection in the General Population and in Populations at Increased Risk for COVID-19
Past Federal grant forecast Posted
- Opportunity number
- RFA-IP-22-003
- Agency
-
Centers for Disease Control and Prevention
Department of Health and Human Services
- Applications expected due
- Award size
- $3,000,000 to $4,000,000
Opportunity facts
- Expected posting
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- City/Township Governments
- 501(c)(3) Nonprofits
- Special District Governments
- Other
- Tribal Organizations (Not Federally Recognized)
- Non-501(c)(3) Nonprofits
- County Governments
- State Governments
- Higher Education Inst. (Private)
- Tribal Governments (Federally Recognized)
- Public or Indian Housing Auth.
- Independent School Districts
- Higher Education Inst. (Public)
Opportunity details come from Grants.gov. Updated .
Forecast synopsis
The purpose of this notice of funding opportunity (NOFO) is to support research to evaluate the long-term effectiveness of COVID-19 vaccines against symptomatic and asymptomatic infections through long-term follow-up of vaccinated individuals (adults and children) and to assess immune response metrics, symptoms, and the development of asymptomatic infection/viral shedding. Studies should be adequately powered to generate product- and variant-specific vaccine effectiveness estimates and to assess risk factors for vaccine breakthrough, including demographic, immunologic, and virologic risk factors, where possible.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity